Various vaccine platforms are geared against COVID-19 vaccine development to produce immunogens in cells. To design a recombinant protein-based COVID-19 vaccine, Vaxine pty Ltd used computer models of the spike protein and its human receptor, ACE2, to identify how the virus infects human cells. Based on this, the COVAX-19Ⓡ vaccine is synthesized. It does reduce not only COVID-19 disease but also blocks virus shedding and transmission. Researchers are optimistic that this vaccine candidate could be clinically available soon with sufficient vaccine efficacy with a considerable amount of reduction in vaccination-related side effects.
|Number of pages||4|
|Journal||Clinical Complementary Medicine and Pharmacology|
|Early online date||09 Aug 2021|
|Publication status||Published - Dec 2021|